Psychedelic-assisted therapy is an effective treatment for treatment-resistant depression

What's this about?

People disagree about whether psilocybin therapy can help adults with hard-to-treat depression.

Psilocybin is a drug from some mushrooms, used with talk therapy and close care.

What supporters say

• Several large reviews found that psilocybin helped ease depression more than other care.
• Tests found fewer signs of depression for a short time after psilocybin, talk therapy, and close support.

What critics say

• People can often tell if they got psilocybin, so their hopes may make the treatment seem better.
• We are not sure if the good effects last after the study ends.
• People in these studies may not match the wider group of patients seen in normal care.

How to read this

The number of points on each side does not show which side is right; strong proof matters more.

The bottom line

The evidence leans toward psilocybin therapy helping some chosen adults, mainly for short-term relief.

We still need longer tests in more kinds of patients before we know how well it works in normal care.

The claim is that psilocybin-assisted therapy can help adults whose depression has not improved enough with earlier treatments. The evidence is encouraging, but its strongest support is for short-term symptom relief in carefully selected patients receiving intensive psychological support.

The case for

Controlled research has found an antidepressant effect. In a randomized phase 2 trial, adults with treatment-resistant depression who received a 25-milligram dose of psilocybin, alongside psychological support, had fewer depressive symptoms three weeks later than those given a 1-milligram control dose. An earlier feasibility study also found rapid improvement after two supported sessions, although its open-label design could not separate the drug’s effects from expectations or other aspects of therapy. 1 (see Figure 2)

The broader research record points in the same direction. Systematic reviews and meta-analyses generally find better depression outcomes with psilocybin than with control treatments, including signs that larger doses may produce larger effects. These findings suggest the result is not limited to a single trial. 2 (see Figure 3)

That support comes with limits. The studies differ in the amount and type of psychological support they provide, often involve small numbers of participants, and usually follow patients for only a short time. Some pooled research examines major depression generally rather than treatment-resistant depression specifically. Even so, the overall evidence supports a high-confidence but qualified conclusion that psilocybin-assisted therapy can improve symptoms for some carefully selected adults, especially in the short term.

The case against

The clearest concern is that the trials may make the treatment look more effective than it is. Participants and therapists can often tell whether psilocybin was given because of its distinctive effects. That makes it difficult to maintain a convincing blind comparison, and expectations can influence people’s reports of subjective symptoms. This does not prove that psilocybin has no real antidepressant effect, but it weakens the claim that differences between treatment and control groups measure the drug alone. 3

The evidence also says much less about whether improvements last. Most randomized trials have short follow-up periods. Longer-term findings in treatment-resistant depression mainly come from observational studies, which lack a control group and may lose participants over time. They also tend to include people who completed earlier research. As a result, it remains unclear how often benefits persist, whether repeated doses are needed, or how the treatment compares with established options over several months or years. 4

The trial participants may not reflect ordinary patients. Studies commonly exclude people at risk of psychosis or mania, those with unstable medical conditions or substance-use problems, and people with acute suicidal thoughts. Participants also receive extensive preparation, supervision and monitoring that may not be available in routine services. 5 The treatment is therefore best understood as a structured package of psilocybin, therapy and clinical oversight—not as unsupervised psychedelic use.

Safety also depends on that setting. Acute anxiety, confusion, physical effects, suicidal thoughts and self-injury have been reported, while small samples and inconsistent follow-up make rare or delayed harms difficult to measure. The research suggests risks are usually manageable under supervision, but it does not establish the same balance of benefits and harms outside specialized care.

The bottom line

The evidence favours the claim, but with important qualifications. Psilocybin-assisted therapy probably can reduce depressive symptoms for some carefully screened adults with treatment-resistant depression, particularly over the short term and when delivered with psychological support. The support for short-term improvement is stronger than the evidence for lasting remission or superiority over standard treatments.

The main uncertainties are substantial: imperfect blinding and expectancy may inflate benefits, long-term controlled evidence is limited, and trial participants differ from many real-world patients. The findings justify confidence in a supervised treatment model, but not in durable effects, broad clinical safety, or unsupervised use.